Agonist
Back to library
GLP-1Subcutaneous

Retatrutide

Also known as: LY3437943 · Reta · Triple-G

Triple agonist at GLP-1, GIP, and glucagon receptors. The glucagon component drives additional energy expenditure and hepatic lipid mobilization beyond dual agonists.

At a glance

Half-life
6 days
Common route
Subcutaneous
Typical dose range
500–12,000mcg
Stability (reconstituted)
30days refrigerated

Best timing

Once weekly. Slow titration is essential — community reports significant GI burden if escalated faster than the trial protocol.

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • History of pancreatitis
  • Active eating disorder
  • Pregnancy

Watch symptoms

  • Severe nausea, vomiting at higher doses
  • Heart rate elevation (more pronounced than other GLP-1s due to glucagon agonism)
  • Elevated liver enzymes
  • Hypoglycemia if stacked with insulin or sulfonylureas
  • Mood changes, fatigue during titration

Citations

The primary literature.

  1. 01Triple-Hormone-Receptor Agonist Retatrutide for ObesityPubMed
  2. 02Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 DiabetesPubMed
Back to library